

Perspectives

Quo Vadis Influenza?

Gabriele Neumann^{1,†}; Yoshihiro Kawaoka^{1,2,3,†}

ABSTRACT

The number of influenza virus detections declined tremendously after the emergence and worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); an effect most likely caused by non-pharmaceutical interventions to slow the spread of SARS-CoV-2. Recent data suggest that influenza virus detection has slightly increased in parts of the world, perhaps owing to the relaxation of social distancing measures.

Influenza A viruses of the H1N1 and H3N2 subtypes and influenza B viruses of the Yamagata and Victoria lineages cause annual epidemics in human populations with spikes in circulation during the winter months in the Northern and Southern hemispheres, and year-round circulation in tropical and subtropical climates.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in December 2019 and spread so rapidly around the world that the World Health Organization (WHO) declared a pandemic on March 11, 2020 (1). As of November 23, 2021, more than 258 million cases of SARS-CoV-2 had been reported with more than 5.1 million fatalities (2).

With the rapid spread of SARS-CoV-2 around the world, the rate of influenza virus detection declined dramatically (3–6). WHO Influenza Update No. 376 (7) reported that of 145,068 specimens tested from August 17 to 30, 2020, only 34 were positive for influenza virus (0.02%). During a similar time period in 2019, 4,097 of 57,132 specimens (i.e., 7.2%) were positive for influenza viruses (8). Similarly, of 200,863 specimens tested from December 21, 2020 through January 3, 2021, only 409 were positive (0.2%) (9) while between December 23, 2019 and January 5, 2020, 44,847 of 174,604 specimens were positive (25.7%) (10).

Several hypotheses have been proposed to explain

the substantial decline in influenza virus detection rates. First and foremost, non-pharmaceutical intervention strategies including social distancing; travel restrictions; closure of schools, universities, and many public and commercial offices; mask wearing; and improved hand hygiene may have curbed the spread of influenza viruses. In addition, viral interference, whereby innate immune responses to a viral infection can affect infection by a second virus (11–14) have been discussed as a potential mechanism that might explain the low rates of influenza virus circulation in human populations during the SARS-CoV-2 pandemic. However, several studies have demonstrated that influenza viruses can replicate in animals or cells co- or sequentially infected with SARS-CoV-2 (15–17), suggesting that viral interference may not be the major reason for the low influenza virus detection rate during the SARS-CoV-2 pandemic. Interestingly, the decline in detection rates differs among human respiratory viruses. Human coronaviruses, parainfluenza viruses, human metapneumoviruses, respiratory syncytial virus, and adenoviruses have all been detected at very low rates since the outbreak of the SARS-CoV-2 pandemic, whereas rhinoviruses have been detected more frequently (4–5,18), perhaps because of their lower sensitivity to alcohol and detergents compared to other enveloped human respiratory viruses. These findings lead to interesting questions about the similarities and differences among human respiratory viruses regarding their transmission mode and the most effective mitigation strategies.

Many of the influenza viruses isolated in 2020 and 2021 originate from the (sub)tropical regions of the world, where the year-round circulation of influenza viruses (believed to be a consequence of climate and behavioral factors) may have supported low-level influenza virus transmission in communities during the SARS-CoV-2 pandemic. Approaching the influenza virus season in the Northern hemisphere, combined with less restrictive non-pharmaceutical interventions in parts of the world due to increasing SARS-CoV-2 vaccination rates, it will be interesting to see whether

influenza viruses make a comeback as major human respiratory pathogens. The latest WHO Influenza Update (19) showed that of 307,999 specimens tested worldwide, 2,199 were positive for influenza viruses, resulting in a detection rate of 0.7%. While this worldwide detection rate is still much lower than prior to the SARS-CoV-2 pandemic, it may suggest increasing influenza virus activity compared to 2020. In particular, parts of Asia (including India and Nepal) have recently experienced increased influenza activity with the number of influenza virus-positive specimens reaching about 50% of the numbers reported before the pandemic (Figure 1); moreover, China has

experienced low levels of B/Victoria virus circulation in 2021 (Figure 1).

The massive reduction in the number of circulating human influenza viruses likely created a substantial genetic bottleneck. In fact, the influenza A and B viruses isolated in 2020 and 2021 fall into a limited number of (sub)clades, while other (sub)clades have virtually disappeared, although viruses of these (sub)clades may still be circulating at low levels. Most noticeably, influenza B viruses of the Yamagata lineage have been detected at very low levels; for example, of 1,176 influenza B viruses reported in the last WHO Influenza Update (19), only one belonged to the




FIGURE 1. Number of influenza virus-positive samples since 2018 in China, India, and Nepal. Figure generated from (20).

Yamagata lineage. Currently, it is not clear why certain influenza virus (sub)lineages have declined more than others during the SARS-CoV-2 pandemic. Several factors including population immunity, viral fitness, and the extent of non-pharmaceutical interventions in the areas of virus circulation may have contributed.

In summary, we are currently experiencing an extraordinary event in human influenza virus epidemiology and evolution during which the virus has experienced extreme pressure that may result in major genetic bottlenecks that could shape influenza virus evolution for years to come. With the expected comeback of human influenza virus infections in the ensuing years, which may be fueled by a waning of immune responses in previously exposed people and an increasing number of infants and toddlers who are naïve to influenza viruses, much can be learned about the evolution and spread of influenza viruses in humans.

Acknowledgments: Susan Watson.

Funding: Supported by Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development (AMED) (JP21wm0125002).

doi: 10.46234/ccdcw2021.254

Corresponding authors: Gabriele Neumann, gabriele.neumann@wisc.edu; Yoshihiro Kawaoka, yoshihiro.kawaoka@wisc.edu.

¹ Influenza Research Institute, University of Wisconsin-Madison, Madison, WI, USA; ² Institute of Medical Science, University of Tokyo, Tokyo, Japan; ³ Research Center for Global Viral Diseases, National Center for Global Health and Medicine, Tokyo, Japan.

Submitted: October 19, 2021; Accepted: November 24, 2021

REFERENCES

- World Health Organization. Timeline: WHO's COVID-19 response. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline>. [2021-9-22].
- Worldometers. Reported cases and deaths by country or territory. <https://www.worldometers.info/coronavirus/#countries>. [2021-11-23].
- Sullivan SG, Carlson S, Cheng AC, Chilver MB, Dwyer DE, Irwin M, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. *Euro Surveill* 2020;25(47):2001847. <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001847>.
- Tang JW, Bialasiewicz S, Dwyer DE, Dilcher M, Tellier R, Taylor J, et al. Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. *J Med Virol* 2021;93(7):4099 – 101. <http://dx.doi.org/10.1002/jmv.26964>.
- Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic — United States, 2020–2021. *MMWR Morb Mortal Wkly Rep* 2021;70(29):1013 – 9. <http://dx.doi.org/10.15585/mmwr.mm7029a1>.
- Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased influenza activity during the COVID-19 pandemic — United States, Australia, Chile, and South Africa, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(37):1305 – 9. <http://dx.doi.org/10.15585/mmwr.mm6937a6>.
- World Health Organization. Influenza update N° 376. <https://www.who.int/publications/m/item/influenza-update-n-376>. [2020-9-14].
- World Health Organization. Influenza update N° 350. <https://www.who.int/publications/m/item/influenza-update-n-350>. [2019-9-16].
- World Health Organization. Influenza update N° 385. <https://www.who.int/publications/m/item/influenza-update-n-385>. [2021-1-18].
- World Health Organization. Influenza update N° 359. <https://www.who.int/publications/m/item/influenza-update-n-359>. [2020-1-20].
- Laurie KL, Guarnaccia TA, Carolan LA, Yan AWC, Aban M, Petrie S, et al. Interval Between infections and viral hierarchy are determinants of viral interference following influenza virus infection in a ferret model. *J Infect Dis* 2015;212(11):1701 – 10. <http://dx.doi.org/10.1093/infdis/jiv260>.
- Wu AC, Mihaylova VT, Landry ML, Foxman EF. Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study. *Lancet Microbe* 2020;1(6):E254 – E62. [http://dx.doi.org/10.1016/S2666-5247\(20\)30114-2](http://dx.doi.org/10.1016/S2666-5247(20)30114-2).
- George JA, AlShamsi SH, Alhammadi MH, Alsuwaidi AR. Exacerbation of influenza a virus disease severity by respiratory syncytial virus co-infection in a mouse model. *Viruses* 2021;13(8):1630. <http://dx.doi.org/10.3390/v13081630>.
- Shinoh M, Omoe K, Saito N, Matsuo N, Nerome K. In vitro growth profiles of respiratory syncytial virus in the presence of influenza virus. *Acta Virol* 2000;44(2):91–7. <https://pubmed.ncbi.nlm.nih.gov/10989700/>.
- Li H, Zhao X, Zhao YR, Li J, Zheng HW, Xue MY, et al. H1N1 exposure during the convalescent stage of SARS-CoV-2 infection results in enhanced lung pathologic damage in hACE2 transgenic mice. *Emerg Microbes Infect* 2021;10(1):1156 – 68. <http://dx.doi.org/10.1080/22221751.2021.1938241>.
- Zhang AJ, Lee ACY, Chan JFW, Liu FF, Li C, Chen YX, et al. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. *Clin Infect Dis* 2021;72(12):e978 – 92. <http://dx.doi.org/10.1093/cid/ciaa1747>.
- Bao LL, Deng W, Qi FF, Lv Q, Song ZQ, Liu JN, et al. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. *Signal Transduct Target Ther* 2021;6(1):200. <http://dx.doi.org/10.1038/s41392-021-00618-z>.
- Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, et al. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. *Influenza Other Respir Viruses* 2021;15(4):488 – 94. <http://dx.doi.org/10.1111/irv.12854>.
- World Health Organization. Influenza update N° 406. <https://www.who.int/publications/m/item/influenza-update-n-406>. [2021-11-8].
- World Health Organization. FluNet. <https://www.who.int/tools/fluNet>. [2021-11-9].